A short-chain poly(thioketal) ("PTK") polymer is provided. The polymer is produced by a method comprising reacting 2,2 dimethoxypropane (DMP) or a ketone with a dithiol monomer in the presence of an acid using a nitrogen atmosphere and stirring for a period of time from 1 to 72hrs. The ketone is selected from the group consisting of acetone, levulinic acid, pyruvic acid, sulfonyl acetone, and oxoglutaric acid.
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 27/42 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice inorganique
C07C 323/12 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné ayant les atomes de soufre des groupes thio liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé
Provided herein are compositions including a functionalized particle, optionally a liposome and a peptide tethered to the liposome, wherein the peptide is selected from a triple-helix forming peptide (THFP), a hyaluronic acid binding peptide (HBAP), or a combination thereof. Also provided herein are methods of using the functionalized particles in increasing residence time of a therapeutic agent in a target treatment area for use in drug delivery and/or treating, eradicating, or inhibiting biofilm formation.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
3.
SUICIDAL THOUGHTS AND BEHAVIOR PREDICTIONS AND TREATMENT
Certain aspects of the disclosure provide systems and methods for diagnosis and treatment of suicidal thought and behavior (STB) through reward-aversion judgment and contextual variables. Methods include generating a set of STB parameters associated with a subject, the set of STB parameters based on reward-aversion judgment variables and contextual variables and processing the set of STB parameters with a machine learning model to generate an STB prediction. The subject may then be treated based on the STB prediction.
A61B 5/16 - Dispositifs pour la psychotechnieTest des temps de réaction
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
4.
MULTIMODE SENSOR INTEGRATION ONTO NEEDLE-BASED SENSING SYSTEMS
A wearable device for sensing at least one analyte in a biofluid is provided. The wearable device includes at least one feature configured to penetrate a skin of a use. The wearable device further includes a first sensor coupled to the feature, the first sensor configured to detect a first analyte. wherein the first sensor is in fluid communication with the feature. The wearable device further includes a second sensor configured to detect a second analyte. the second analyte being an analyte different from the first analyte. wherein the second analyte is in fluid communication with the feature.
A61B 5/1486 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques en utilisant des électrodes enzymatiques, p. ex. avec oxydase immobilisée
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
5.
Recapitulating Tissue-Native Architectures in Bio-printable Hydrogels
A device for modelling physiological and pathophysiological states of the brain is provided. The device comprises a hydrogel with micropattern channels having a length, width and depth. The micropattern channels comprise cells selected from the group consisting of neurons, astrocytes, microglia, oligodendrocytes, neuronal organoids, cancer cells, cancer spheroids, brain tumoral cells and combinations thereof.
B33Y 80/00 - Produits obtenus par fabrication additive
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
The present technology is directed to a method of treating a cancer, or multiple cancers, comprising administering to said individual one or more compounds selected from a VAV3-inhibitor such as IODVA1, followed by administration of a selective estrogen receptor modulator (SERM) and/or selective estrogen receptor degrader (SERD), to an individual in need thereof. In embodiments, the administration may be concurrently with or following IODVA1 administration.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
7.
SYSTEMS AND METHODS FOR EVALUATING AN OSCILLATORY MOTION REGULATORY DEVICE
A system and method for evaluating an oscillatory motion regulating device include a base, an oscillation mechanism, a motion sensor, and one or more processors. The base includes a plate body and an edge beam. The plate body has an upper surface, a lower surface opposite to the upper surface, and three or more edges. The edge beam is extended from one of the edges, the edge beam is configured to be mechanically attached to an oscillatory motion regulating device. The oscillation mechanism is mechanically coupled to the upper surface of the plate body. The motion sensor is operable to monitor an oscillatory motion of the base. The one or more processors are configured to cause the motion sensor to generate an oscillatory motion data of the base.
G05D 1/49 - Commande de l’attitude, c.-à-d. commande du roulis, du tangage ou des embardées
B62D 37/06 - Stabilisation des caisses de véhicules sans agir sur les dispositifs de suspension au moyen de masses mobiles en utilisant des gyroscopes
B63B 39/04 - Installations pour diminuer le tangage, le roulis ou autres mouvements similaires indésirables du navireAppareils pour indiquer l'assiette du navire réduisant les mouvements du navire par l'effet direct de gyroscopes
Described herein are CDK9 degraders that include a CDK9 binding moiety, such as AT7519 or VIP152, conjugated to a E3 ubiquitin ligase binding moiety, such as thalidomide, lenalidomide, or pomalidomide. These degraders can induce the ubiquitination of CDK9 and promote its degradation in cells. The linker covalently tethering the CDK9 binding moiety to the E3 ubiquitin ligase binding moiety can be selected to tune the solubility profile and potency of the degrader. Accordingly, the present disclosure provides compounds, compositions, kits, uses, and methods for the treatment of cancer (e.g., blood cancers such as acute myeloid leukemia or acute lymphoblastic leukemia).
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
9.
DEUTERATED BENZODIAZEPINE ANALOGS AND METHODS OF USE IN TREATING CANCER
Provided herein are benzodiazepine analogs according to the following formula: (I) wherein: R1 is selected from the group consisting of hydrogen, halo, methyl, ethyl, trideuteromethyl, trifluoromethyl, and cyclopropyl; and R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, tritium, and methyl. Pharmaceutical compositions including Formula I compounds and methods of treating cancer by administering Formula I compounds are also provided herein.
Methods and systems for delivery of pulsated air to a user using a device including a flow generator to generate a continuous air flow, a first actuator comprising a pulsated flow delivery mechanism configured to generate a pulsated air flow from the continuous air flow based on a pre-determined duty cycle to vary a frequency of the pulsated air flow, a user interface configured to generate and deliver vortices of pulsated air to the user at the frequency of the pulsated air flow, and a set of tubing to couple the flow generator, the first actuator, and the user interface.
The present invention involves a method of targeted imaging of a bacterial infection in a subject. In one embodiment, the method includes administering pyochelin (PcH) bound to a radiometal to the subject and imaging the infected area of the subject using a positron emission tomography-computed tomography (PET/CT) scan. In one embodiment, the pyochelin bound to a radiometal is selected from the group consisting of copper-64 bound pyochelin and gallium-68 bound pyochelin.
A method of treating cancer metastasis in a subject in need thereof is provided, the method including administering to the subject a combination therapy including: (a) a vascularization and/or tissue remodeling inhibitor; (b) a suppressor of oxidative metabolism; and (c) an ion homeostasis modulator. Pharmaceutical compositions directed to the combination of therapeutic agents are also provided.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A novel genetically modified bacterium is disclosed. The bacterium has one or more anti-spike glycoprotein nanobodies on the outer membrane of the bacterium. In one embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Intimin. In another embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Lpp-OmpA.
A method for performing an analysis related to potential rejection of an organ after transplantation in a subject is provided. The method involves identifying alloreactive/expanded CD8 T cell clones in either an allograft biopsy or a urine sample from the subject, wherein the T cell clones are identified using a single cell RNASeq (scRNAseq)/TCRseq test. In one embodiment, the analysis is selected from the group consisting of detection of rejection, diagnosis of rejection, treatment selection, therapeutic monitoring for rejection, identification of resistance to rejection treatment, and combinations thereof.
Systems and methods for delivering a drug to a patient's kidney. The present systems comprise a urethral catheter and a ureteral catheter sized to fit through the urethral catheter. The urethral catheter includes a balloon configured to be inflated in the patient's bladder to retain the urethral catheter in the patient's urethra. The ureteral catheter includes a balloon configured to be inflated in the patient's ureter and/or kidney while a distal end of the ureteral catheter is disposed in the patient's kidney. The ureteral catheter balloon can help retain liquid in the kidney to enable expanded contact areas with kidney tissues and extended dwell times (e.g., periods of exposure) of the drug in the kidney. The balloons also help retain the catheters in the patient's urinary tract, such that the catheter system can be used to deliver a drug to the patient's intermittently or periodically over a period of days or weeks.
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
16.
METHODS OF POTENTIATING TEMOZOLOMIDE ACTIVITY AGAINST GLIOBLASTOMA CELLS
Provided herein is a method of potentiating a cytotoxic effect of temozolomide against glioblastoma cells in a subject in need thereof, the method including administering to the subject a combination of: a therapeutically effective amount of temozolomide; and a non-cytotoxic amount of letrozole, wherein the letrozole potentiates the cytotoxic effect of the temozolomide against the glioblastoma cells. Also provided is a method of restoring sensitivity of temozolomide-resistant glioblastoma cells to temozolomide, including contacting the glioblastoma cells with a non-cytotoxic amount of letrozole and method of treating glioblastoma.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/175 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine ayant le groupe , N-C(O)-N=N- ou , p. ex. carbonohydrazides, carbazones, semicarbazides, semicarbazonesLeurs thio-analogues
A device for measuring an analyte comprises a sensor including an electrode with an aptamer and an attached redox couple. The sensor is adapted to electrochemically measure a change in concentration of the analyte. The device further comprises a detection circuit configured to select a sampling frequency at which a measurement is taken. The detection circuit is further configured to periodically apply an input voltage to an electrode to obtain a measured response of the electrode. The measured response includes a target signal of the aptamer and an artifact. The detection circuit is further configured to detect the artifact using a transformative tool. The detection circuit is further configured to apply a filter to the measured response of the electrode to attenuate or remove the artifact. The detection circuit is further configured to measure the analyte using the target signal and not the artifact.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio
G01N 27/00 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques
G01N 27/30 - Électrodes, p. ex. électrodes pour testsDemi-cellules
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
18.
ADVANCED SAMPLING METHODS FOR FASTER MOLECULAR SENSOR RESPONSE TO HIGHLY DILUTE ANALYTES
A method for continually sensing at least one analyte. The method includes bringing a sample including at least one analyte into contact with at least one sensor having an electrode and a plurality of aptamers that are capable of binding to the analyte. At least some of the aptamers each carry at least one tag (such as a redox tag), wherein each tag changes in at least one parameter when analyte binds to its associated aptamer (such as by being brought closer to or further from, on average, the electrode (which results in a measurable change in electrical current that can be translated to a measure of presence or concentration of the analyte). The method also includes applying a first electronic waveform to the at least one sensor, wherein the first electronic waveform is associated with a first binding affinity between the analyte and the plurality of aptamers. The method also includes applying a second electronic waveform to the at least one sensor, wherein the second electronic waveform is associated with a second binding affinity between the analyte and the plurality of aptamers. The first electronic waveform and second electronic waveform are different waveforms, and the first binding affinity and second binding affinity differ by at least 2X.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
19.
DEVICES AND METHODS FOR SIMULTANEOUS MECHANOCHEMICAL AND ELECTROCHEMICAL REACTIONS
The present invention is directed to a method and apparatus for simultaneously implementing mechanochemical and electrochemical synthesis conditions. With respect to the method, the method may be configured to improve one or more reaction metric such as increasing product yield, reducing organic solvent consumption, reducing the reaction time, reducing the amount of, or completely eliminating, at least one toxic reagent or solvent, or enabling electrochemical synthesis of the chemical product without complete solubility of the organic substrate in the organic solvent. With respect to the apparatus, the apparatus is configured to define a reaction area between an anode and cathode that can be mechanochemically agitated to improve synthesis without disrupting the electrochemical reaction.
Provided herein are compositions including ionizable lipids and lipid nanoparticles comprising the ionizable lipids. The ionizable lipids may have a general structure according to formula I: (I). Lipid nanoparticles generally include the ionizable lipid according to formula (I); a helper lipid; a sterol; and a PEGylated lipid conjugate. The ionizable lipids and lipid nanoparticles may be used to carrier cargo for a vaccine.
C07D 211/62 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile liés en position 4
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
21.
Single Waveform, Continuous Squarewave Voltammetry for Optimal Calibration Free Sensing
A method of measuring sensor response for a sample is disclosed. The sample is exposed to an electrochemical aptamer-based (EAB) sensor, where the sensor includes an electrode and one or more aptamers having redox tags. Next, an interrogation is performed by applying an abrupt voltage pulse to the electrode. Two or more data samples are collected at different time values, where each data sample is a redox tag current value. Then at least one measure of the sample is identified using the data samples.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
22.
Promotion of Cardiomyocyte Proliferation and Regenerative Treatment of the Heart by Inhibition of microRNA-128
A complex of curcumin with a polyphenolic macrocyclic host is disclosed. The macrocyclic host is a resorcin[4] arene. In one approach, the polyphenolic macrocyclic host is calix[8] arene. In another approach, the polyphenolic macrocyclic host is tert-butylcalix[8] arene.
Methods of treating lung cancer in a subject in need thereof are provided, including administering to the subject an effective amount of an imidazolate gold compound according to Formula I, or a pharmaceutically acceptable salt, racemate, or enantiomer thereof:
Methods of treating lung cancer in a subject in need thereof are provided, including administering to the subject an effective amount of an imidazolate gold compound according to Formula I, or a pharmaceutically acceptable salt, racemate, or enantiomer thereof:
Methods of treating lung cancer in a subject in need thereof are provided, including administering to the subject an effective amount of an imidazolate gold compound according to Formula I, or a pharmaceutically acceptable salt, racemate, or enantiomer thereof:
wherein R1 and R2 are independently selected from the group consisting of halo, cyano, hydroxyl, carboxyl, alkyl, aryl, esteryl, amidyl, and alkoxyl. Methods of inducing ferroptosis in a lung cancer cell and pharmaceutical compositions are also provided.
A method of determining platelet aggregation forces is provided. The method involves embedding tension sensor-coated microbeads in platelet clots and observing fluorescent signals from the microbeads that correspond to contractile forces exerted on the tension sensor-coated microbeads to report platelet aggregation forces. In one embodiment, the platelet aggregation forces are used as biomechanical markers to evaluate platelet functions. In another embodiment, the fluorescent signals can be read directly by a plate reader.
G01N 11/14 - Recherche des propriétés d'écoulement des matériaux, p. ex. la viscosité, la plasticitéAnalyse des matériaux en déterminant les propriétés d'écoulement en déplaçant un corps à l'intérieur du matériau en utilisant des corps en rotation, p. ex. moulinet
G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
26.
Lift-Based Peel Separation for Inverted Vat Photopolymerization 3D Printing
A method of inverted SLA 3D printing with a printing device is disclosed. The method involves a) lifting a thin elastic membrane to an elevated position within a resin filled vat via vertical movement of an optical module, the resin filled vat, or both. b) allowing resin on the thin elastic membrane to cure as a current layer, the layer being attached to a printed part, and c) peeling the thin elastic membrane from the current layer by lowering the optical module, raising the resin filled vat, or both.
B29C 64/124 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective
A device and method for detecting the presence of, or measuring the concentration or amount of, at least one large analyte in a sample fluid. The device has at least one electrode, a sample fluid and a plurality of aptamers capable of binding to the analyte. The aptamers are physically bound to the device. In addition, the aptamers each include at least one redox tag and also, the aptamers have two or more binding portions that bind to two or more distinct binding sites on the analyte in the sample fluid.
Certain aspects of the disclosure provide systems and methods for generating predictions of mood disorder. For example, one method may include presenting a set of stimuli and receiving a set of ratings for the set of stimuli from a subject. The method further includes determining a set of judgment variables based on the set of ratings. The method further incudes generating a mood disorder prediction based on the set of judgment variables and treating the subject based on the mood disorder prediction.
G16H 50/00 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies
G16H 10/00 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients
G16H 40/00 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
H01M 4/90 - Emploi de matériau catalytique spécifié
H01M 10/056 - Accumulateurs à électrolyte non aqueux caractérisés par les matériaux utilisés comme électrolytes, p. ex. électrolytes mixtes inorganiques/organiques
H01M 12/06 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type élément primaire avec une électrode métallique et une électrode à gaz
A method to prevent calcification of an injury site in a subject is provided. The method involves injecting the injury site with a composition including a hydrogel and the hydrogel comprises poly(aspartic acid) (PASA). In one embodiment, the hydrogel is formed by combining thiol- functionalized PASA with one or more maleimide-functionalized crosslinkers. Additionally, a method to prevent premature bone fusion in a pediatric subject's skull is provided. The method involves injecting one or more cranial sutures of the skull with a composition including a hydrogel and the hydrogel comprises poly(aspartic acid) (PASA).
A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
C08J 3/09 - Production de solutions, dispersions, latex ou gel par d'autres procédés que ceux utilisant les techniques de polymérisation en solution, en émulsion ou en suspension dans des liquides organiques
C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
C08L 29/02 - Homopolymères ou copolymères d'alcools non saturés
31.
Electrochemical Aptamer Sensors with Signal Amplification Via Multiple Redox Tags
A device for detecting the presence of, or measuring the concentration or amount of, at least one analyte in a sample fluid is disclosed. The device includes at least one electrode; a sample fluid; and a plurality of affinity-based probes capable of binding to the analyte, wherein the affinity-based probes each carry a plurality of redox tags. Further, the detection or measurement of an analyte is caused by analyte binding to the affinity-based probe which further causes a change in electron transfer from the redox tags.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
32.
Personalized Medicine Platform to Dissect Brain Tumor Microenvironment and Rapidly Test Therapeutic Efficacy
A device for modeling a brain tumor microenvironment and testing therapeutic efficacy is provided. The device includes a vascular tissue model and an ultrasound device that is capable of delivering focused ultrasound insonation. The vascular tissue model includes a rigid 3D printed scaffold. The scaffold includes one or more scaffold microfluidic channels, two or more inlets, and a central chamber. The central chamber contains a hydrogel or other biocompatible scaffolds. The hydrogel includes one or more hydrogel microfluidic channels as well as living cells.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
B33Y 80/00 - Produits obtenus par fabrication additive
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
Certain aspects of the disclosure provide systems and methods for diagnosing and treating chronic liver disease and portal vein thrombosis. In particular, methods may include measuring levels of one or more proteins, including factor V, factor VIII, protein C, protein S, D-dimer, sP-selectin, or asTF in a biological sample from a subject and determining a CLD score based on the levels of the one or more proteins, whereby, a CLD stage may be determined based on the CLD score. In some aspects, methods may include determining a PVT score based on levels of the one or more proteins in the biological sample. In some aspects, methods further include treating CLD and/or PVT.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/84 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des composés inorganiques ou le pH
34.
Method and Device for Endoscopic Endonasal Occipitocervical Fusion
A novel endonasal method for occipitocervical fusion is provided. This new method provides a minimally invasive advance in the ability of surgeons to treat pathology of the craniocervical junction. The method uses an implant system comprising a body having a spacer section that engages with the occipital condyle and a plate section that engages with the C1 lateral mass. Fasteners fix the plate section with the occipital condyle the plate section with the C1 lateral mass.
A61B 17/70 - Dispositifs de mise en position ou de stabilisation de la colonne vertébrale, p. ex. stabilisateurs comprenant un liquide de remplissage dans un implant
35.
ELECTROCHEMICAL AFFINITY BIOSENSORS WITH SENSOR RESPONSE DEPENDENT ON PROXIMITY OF TWO OR MORE TAGS
A device for detecting or measuring at least one large analyte in a sample fluid. The device includes at least one electrode; a sample fluid; and a plurality of aptamers capable of binding to the analyte, wherein the aptamers are physically bound to the device. A majority of the aptamers comprise a first molecule and a second molecule. The first molecule is a redox tag or redox molecule. The second molecule, when it is brought into proximity of the first molecule, results in decreased redox electron transfer with an electrode at a given voltage.
Provided herein is a device for rapid fixation and embedding of a biological specimen, the device including a barrel having a first end and a second end, the first end receiving a plunger and the second end opening to a compartment defining a block mold; and a plunger for inserting in the barrel, the plunger having a first end, a second end, and an interior conduit connecting the first and second ends, wherein the first end of the plunger connects to a vacuum source and the second end of the plunger includes a filter barrier between the interior conduit of the plunger and a receptacle for receiving, fixing, and embedding the specimen, the receptacle defined inside the barrel when the plunger is disposed in the barrel. Also provided are a system and method for rapid fixation and embedding of a biological specimen.
A novel method for treating hyponatremia or polycystic kidney disease in a mammal is disclosed. The method involves administering to the mammal in need of such treatment a therapeutically effective amount of an adenine analog selected from the group consisting of: 2-chloro-6-aminopurine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier, 6-(dimethylamino) purine, its tautomer, racemate, optical isomer and/or pharmaceutically or nutritionally acceptable salt thereof, and a pharmaceutical carrier; and combinations thereof.
A continuous sensing device configured for sensing both oxygen and at least one other analyte in a fluid in a single measurement scan comprising a first electrode. A method of measuring both oxygen concentration and the concentration of at least one other analyte using sensing device comprising a first electrode. The method comprises measuring current in a first potential zone, wherein that current correlates to concentration of the at least one other analyte, and measuring current in a second potential zone, wherein that current correlates to a concentration of oxygen. The method may further comprise configuring the first electrode to measure a greatest measured current over baseline to a maximum within one or both of the two potential zones for a duration.
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/483 - Analyse physique de matériau biologique
Systems, methods, and computer program products for minting non-fungible tokens (52). The system includes a computing device (18, 24) that receives a dynamic uniform resource identifier (URI) (64) including a unique identifier and a hostname that identifies a host system (12). In response to receiving the dynamic URI (64), the computing device (18, 24) transmits data to the host system (12) identified by the hostname. The data includes the unique identifier and at least one of a time the computing device (18, 24) received the URI (64) and a physical location of the computing device (18, 24) when the URI (64) was received. In response to receiving the data from the computing device (18, 24), the host system (12) mints a non-fungible token (52) on a blockchain (30) that documents at least one of the time the computing device (18, 24) received the URI (64) and the physical location of the computing device (18, 24) when the URI (64) was received.
G06F 16/10 - Systèmes de fichiersServeurs de fichiers
G06F 21/73 - Protection de composants spécifiques internes ou périphériques, où la protection d'un composant mène à la protection de tout le calculateur pour assurer la sécurité du calcul ou du traitement de l’information par création ou détermination de l’identification de la machine, p. ex. numéros de série
G06F 21/33 - Authentification de l’utilisateur par certificats
In one aspect of the present invention, a genetically modified Anti-Mullerian Hormone (AMH) is disclosed where one or more cysteine residues in the prodomain are replaced with amino acid residues other than cysteine. In one embodiment, one or more cysteine residues in the prodomain are replaced with serine residues. In one embodiment, cysteine 241 of the prodomain is replaced with a serine residue.
METHODS FOR SELF-SEEDED HYDROTHERMAL GROWTH OF MFI ZEOLITE NANOSHEETS AND NANOSHEET ASSEMBLIES AND FOR TILING NANOSHEET ZEOLITE PLATES ON POLYMER SUPPORTS
The present invention relates to methods for synthesizing MFI zeolite nanosheet (ZN) assemblies and open-pore ZN plates and for tiling ZN plates on polymer supports. Methods for producing ZN assemblies and ZN plates may reduce or eliminate the need to synthesize nanoparticle (NP) seed-evolved single-crystal zeolite nanosheets (ZNs) as an intermediate product. Methods for tiling ZN plates on polymer supports may produce ZN plate-tiled (ZNPT) membranes with reduced permeation through intercrystalline spaces.
B01J 20/10 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant de la silice ou un silicate
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
C30B 7/14 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p. ex. à partir de solutions aqueuses le matériau à cristalliser étant produit dans la solution par des réactions chimiques
A method of making a polyurethane polymerized high internal phase emulsion (polyHIPE) is disclosed. The method involves preparing a polyurethane prepolymer and crosslinking the polyurethane prepolymer using a thiol-alkene Michael addition, producing a polyurethane polymerized high internal phase emulsion. In one embodiment, the polyurethane prepolymer is prepared by reacting diisocyanate and trimethylolpropaneallylether (TMPAE).
C08G 18/67 - Composés non saturés contenant un hydrogène actif
C08G 18/73 - Polyisocyanates ou polyisothiocyanates acycliques
C08G 18/75 - Polyisocyanates ou polyisothiocyanates cycliques cycloaliphatiques
C08G 18/76 - Polyisocyanates ou polyisothiocyanates cycliques aromatiques
C08G 18/87 - Polymères modifiés chimiquement par du soufre
C08J 9/28 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolairesLeur post-traitement par élimination d'une phase liquide d'un objet ou d'une composition macromoléculaire, p. ex. par séchage du coagulum
43.
SYSTEMS AND METHODS FOR AERIAL VEHICLES EQUIPPED WITH CONTROL MOMENT GYROSCOPES
An aerial vehicle system includes one or more actuators; a processor; and a non-transitory, computer-readable storage medium communicatively coupled to the processor. The processor is configured to: receive one or more predetermined state values, wherein the one or more predetermined state values include one or more user values associated with aerial instability including turbulence, motion sickness, or any combination thereof; receive one or more sensing parameters; compare the one or more predetermined state values with the one or more sensing parameters; generate, based on the comparison, one or more signals to stabilize an aerial vehicle; transmit the one or more signals to the one or more actuators; and control, in response to the one or more signals, stabilization of the aerial vehicle by the one or more actuators.
B64C 13/16 - Dispositifs amorçant la mise en œuvre actionnés automatiquement, p. ex. répondant aux détecteurs de rafales
B64C 27/82 - GiravionsRotors propres aux giravions caractérisés par l'existence d'un rotor auxiliaire ou d'un dispositif à jet fluide pour contrebalancer le couple du rotor de sustentation ou faire varier la direction du giravion
G01S 17/50 - Systèmes de mesure basés sur un mouvement relatif de la cible
A method of making sensors with a plurality of aptamers and performing continuous measurements with the sensors is provided. The method involves fabricating a plurality of sensors where each sensor has at least one electrode with a plurality of aptamers attached to the electrode surface. A portion of the plurality of sensors is calibrated and a portion of the plurality of aptamer sensors is identified as being commercial quality ("the product portion"). At least one set of calibration data gathered from the calibration of the plurality of sensors is associated mathematically to the product portion.
A61B 5/1495 - Étalonnage ou test des sondes in vivo
A61B 5/1486 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques en utilisant des électrodes enzymatiques, p. ex. avec oxydase immobilisée
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
45.
SULFONATO RESORCINARENE-COMPLEXED FLUOROQUINOLONES AND METHODS OF USE
Supramolecular inclusion complexes comprising sulfonato methylresorcinarenes according to Formula I and a fluoroquinolone compound are provided. Also provided are pharmaceutical compositions comprising the supramolecular complexes and methods of using the supramolecular complexes to treat bacterial infections, kill or inhibit growth of bacteria, and disrupt bacterial biofilms.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
46.
INDUSTRIAL HEAT PUMPS FOR TRANSPORTING HEAT WITH A REFRIGERANT AND A METHOD OF OPERATING THE SAME
An industrial heat pump includes an evaporator configured to transfer heat into a refrigerant, a condenser configured to transfer the heat out of the refrigerant to a heat sink, a first fluid path, a second fluid path, and an expansion valve defining a portion of the first fluid path. The industrial heat pump includes a thermal storage unit defining a portion of the second fluid path. The thermal storage unit is configured to receive and store heat from the refrigerant in the second fluid path. The industrial heat pump includes a compressor defining a portion of the second fluid path between the thermal storage unit and the condenser. The heat received by the thermal storage unit causes a portion of the refrigerant to phase change from a gas to a liquid allowing for wet compression of the refrigerant through the compressor where the refrigerant phase changes to a gas.
F25B 30/02 - Pompes à chaleur du type à compression
F25B 1/00 - Machines, installations ou systèmes à compression à cycle irréversible
F25B 27/02 - Machines, installations ou systèmes utilisant des sources d'énergie particulières utilisant la chaleur perdue, p. ex. chaleur dégagée par des moteurs à combustion interne
C09K 5/04 - Substances qui subissent un changement d'état physique lors de leur utilisation le changement d'état se faisant par passage de l'état liquide à l'état vapeur ou vice versa
47.
CONTINUOUS EXTRACTION AND SENSING OF INTERSTITIAL FLUID
Described are sensing devices and methods that continuously sense an analyte included in an interstitial fluid. The device includes at least one ex-vivo sensor specific to the a least one analyte in interstitial fluid. The device further includes at least one sample collection component in the dermis that defines at least in part an advective pathway to transport interstitial fluid to the at least one sensor. The advective pathway is air-tight, and at least one integrated pump applies negative pressure to cause advective transport of interstitial fluid from the dermis, to the sensor, and onto the pump.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
A61B 5/1477 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques non invasifs
A61B 5/15 - Dispositifs de prélèvement d'échantillons de sang
48.
APPARATUS WITH 3D MICROFLUIDIC FEATURES FOR IN VITRO CULTURING APPLICATIONS
A three-dimensional microfluidic device is provided. The device includes an array of fluid transporting channels formed in a permeable gel. The channels allow both direct circulation flow and diffusion flow from a channel into the gel. The diffusion flow is lateral to the direction of the channel. The device also includes one or more fluid movement devices capable of controlling the circulation flow to enable control of flow pattern in the permeable gel. The device further includes one or more types of organoids cultured in the device.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
UNIVERSITY OF CINCINNATI (USA)
Inventeur(s)
Deng, Zicheng
Kalinichenko, Vladimir
Shi, Donglu
Abrégé
Polymers based on a poly(β-amino) ester (PBAE) backbone are provided, with improved targeting of the lung endothelium following parenteral delivery. The disclosed polymers are polymers of a primary amine (A2), a secondary amine (A1), a diacrylate (D) and at least one end-capping hydrophilic compound (C) such as amine. The polymer is halogenated (hereinafter, halogenated PBAE polymer), preferably, fluorinated. The hydrophobic PBAE backbone is end capped with a hydrophilic compound by covalent attachment of these capping agents to the PBAE backbones via Michael Addition to form a halogenated PBAE. The disclosed polymers can be used to encapsulate/incorporate an active agent for targeted delivery to lung endothelial cells.
A nozzle (30) for a jet engine (32) is disclosed. The nozzle (30) includes at least one sweeping jet actuator (10) operatively coupled to the nozzle (30). The sweeping jet actuator (10) has an inlet opening (14) and a discharge slot (26). The inlet opening (14) is configured to receive a supply of air (40) and the discharge slot (26) is configured to discharge that supply of air in a sweeping motion (42) into and interacting with an air flow (36) moving through the nozzle (30). A jet engine (32) with a nozzle (30) and a sweeping jet actuator (10) coupled to the nozzle (30) is also disclosed. A method of operating a jet engine (32) having a nozzle (30) with a sweeping jet actuator (10) is further disclosed.
F02K 1/34 - Ensembles fonctionnels caractérisés par la forme ou la disposition de la tubulure de jet ou de la tuyèreTubulures de jet ou tuyères particulières à cet effet utilisant des jets de fluide pour influencer l'écoulement du jet pour atténuer le bruit
F02K 1/38 - Introduction d'air à l'intérieur du jet
51.
AGENTIC ARTIFICIAL INTELLIGENCE SYSTEM FOR EDUCATIONAL ENVIRONMENTS
Methods, systems, and computer program products for providing an educational environment using agentic artificial intelligence. A prompt is received from a system user (220), and a response to the prompt is generated using a large language model (208). The response includes raw content defining a clinical scenario consistent with the prompt. The raw content is interpreted using fuzzy logic (213) to generate filtered content based on the first raw content, and the filtered content is displayed to the user (220). In response to the user (220) inputting additional prompts responsive to the filtered content, the large language model (208) generates another response including raw content that defines an updated clinical scenario consistent with both the initial clinical scenario and the additional prompts received from the user. The fuzzy logic (213) generates new filtered content based on the new raw content, and this filtered content is displayed to the system user (220).
The present invention relates to a catalyst for degrading perfluorooctanoic acid (PFOA) in solution, comprising bimetallic catalytic nanoparticles immobilized on a substrate. The nanoparticles may include metals such as iron, manganese, cobalt, nickel, copper, and titanium. The substrate may be an ion exchange resin, such as an anion exchange resin. Methods for synthesizing the catalyst may include dissolving metal salts in water, titrating with a reducing agent, and immobilizing the nanoparticles on the resin. Methods of degrading PFOA include providing a plurality of bimetallic catalytic nanoparticles to a first solution comprising perfluorooctanoic acid. The method may optionally include additional steps for immobilizing the bimetallic catalytic nanoparticles, synthesizing the bimetallic catalytic nanoparticles, purging the first solution with an inert gas, and/or adjusting the pH of the first solution.
A stent for a bladder is provided. The bladder includes a drainage tube, a shell with flexible leaf-shaped sections ("spring leaves") and a string tether. The shell surrounds the drainage tube and the tether is attached to the drainage tube. In addition, the spring leaves are attached at the top of the drainage tube and the spring leaves are attached at the bottom of the shell by a ring with an opening through which the drainage tube can pass freely.
Myopeptides are provided, which include a myosin S2 fragment having at least 90% sequence identity to an amino acid sequence consisting of VKEMTERLEDEEEMNAELTAKK (SEQ ID NO: 1); and, optionally, a cardiac-homing peptide tag. Also provided are pharmaceutical compositions and methods of use of the myopeptides and pharmaceutical compositions in the treatment of heart failure.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
A method of incorporating one or more linkers into a biomaterial with one or more ketone units is disclosed. The method involves reacting a linker-containing material selected from the group consisting of thiol-containing compositions, thioketal-containing compositions, selenol-terminated compositions and combinations thereof with the biomaterial in the presence of an acid catalyst.
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
The present invention relates to a device for continuous sensing of at least one analyte in a test fluid that is resistant at least one of desorption of a first plurality of molecules, including a plurality of aptamers and a blocking layer, and fouling during use of the device when exposed to temperatures greater than or equal to 30° C. for at least 3 days. Another aspect of the invention is a method of providing fouling resistance to an aptamer sensor device wherein the blocking layer and aptamer are resistant to at least one of desorption from the electrode and fouling during use of the aptamer sensor when exposed to temperatures greater than or equal to 30° C. for at least 3 days.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
57.
A CONSTANT CONVERSION RATE OF ENDOLYSOSOMES REVEALED BY A PH-SENSITIVE FLUORESCENT PROBE
The present disclosure concerns fluorescent probes of pyridine, quinolinium and piperazine covalently linked as a small molecule probe. The probes can be administered to cells and are readily uptaken thereby. The probes locate particularly into endolysosomes. The probes provide two types of fluorescence with pH-sensitive photophysical properties, which in turn allows for the observation and analysis of changes occurring during varying stages of interest. The dual fluorescence provides for simultaneous monitoring of two fluorescence signals in endolysosomes at different stages of interest and minimizes the interference from various microenvironments.
C07D 215/02 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle
C07D 241/04 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07D 213/02 - Composés hétérocycliques contenant des cycles à six chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle et avec au moins trois doubles liaisons entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques comportant trois liaisons doubles
C07D 215/12 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle
A method of measuring analytes in a subject in vivo for a period of time is provided. The method involves storing a device. The device includes at least one sensor comprising an aptamer material; at least one feature for coupling said sensor to an analyte in the subject in vivo; at least one sterilization state that imparts sterilization on at least one component of the device; at least one sterile packaging material enabling a storage state; and at least one aptamer storage material. The sensor is contained in the sterile packaging material and the storage material is anhydrous. Further, wherein the sensor and the feature are sterile. The method further involves removing the sterile packaging material from the device and using the feature to couple the sensor to an analyte in the subject.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/1473 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques invasifs, p. ex. introduits dans le corps par un cathéter
59.
ELECTROCHEMICAL APTAMER SENSOR MONOLAYER INCUBATION WITH IMPROVED STABILITY
A method of fabricating an electrochemical aptamer sensor is provided. The method includes incubating an electrode including a sensing monolayer. The sensing monolayer includes at least a plurality of aptamers and at least one weakly bonded constituent. The method further includes removing the at least one weakly bonded constituent from the sensing monolayer by applying at least one perturbation mechanism to the sensing monolayer while incubating the electrode.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
60.
PHENOLIC COATINGS FOR ENHANCED RESISTANCE TO HYDROCARBON POISONING OF PROTON EXCHANGE MEMBRANE FUEL CELL ELECTRODES
An electrocatalyst ink composition is provided. The ink composition includes a liquid vehicle, particles with at least one electrocatalyst metal, and at least one compound having a phenolic moiety. In various embodiments, the compound comprising a phenolic moiety is resorcinol and the electrocatalyst metal is a platinum-bismuth alloy.
A device for detecting or measuring at least one large analyte in a sample fluid is provided. The device includes at least one substrate and a plurality of multi-bond aptamers capable of binding to the analyte. The aptamers are physically bound to the substrate and include at least one tag capable of providing a signal. Also, the multi-bond aptamer has a change in geometry when the multi-bond aptamer binds to the analyte. Further, the tag has a resulting change in signal resulting from the analyte binding to the multi-bond aptamer and associated change in geometry.
C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
An apparatus may comprise a controller programmed to establish a connection with an integrated circuit, program a plurality of cross-coupled look up tables of the integrated circuit to generate a plurality of memory cells, each pair of cross-coupled look up tables comprising one memory cell, and associate a plurality of the memory cells with a digital fingerprint of the integrated circuit, a value of each memory cell after startup of the integrated circuit comprising one bit of the digital fingerprint.
G06F 21/44 - Authentification de programme ou de dispositif
G06F 21/73 - Protection de composants spécifiques internes ou périphériques, où la protection d'un composant mène à la protection de tout le calculateur pour assurer la sécurité du calcul ou du traitement de l’information par création ou détermination de l’identification de la machine, p. ex. numéros de série
G06F 30/34 - Conception de circuits pour circuits reconfigurables, p. ex. réseaux de portes programmables [FPGA] ou circuits logiques programmables [PLD]
H04L 9/32 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système
22 separation is provided. The sorbent chemical includes an amine functionalized with an epoxide chemical impregnated onto a mesoporous silica support. The amine is selected from the group consisting of polyethylenimine, tetraethylenepentamine, and pentaethylenehexamine. Also, the epoxide chemical is selected from the group consisting of isobutylene oxide (TBO), dimethyl- 1,2-epoxybutane (DMEB), epoxy octane (EO), styrene oxide (SO), phenyl glycidyl ether (PGE), glycidyl 4-methoxyphenyl ether (GMPE), butyl glycidyl ether (BGE), glycidyl isopropyl ether (GIPE), 2- (tert-butoxymethyl oxirane) (TBGE), and neopentyl glycol diglycidyl (NGD).
B01J 20/10 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant de la silice ou un silicate
C08G 59/18 - Macromolécules obtenues par polymérisation à partir de composés contenant plusieurs groupes époxyde par molécule en utilisant des agents de durcissement ou des catalyseurs qui réagissent avec les groupes époxyde
A method of treating pancreatic adenocarcinoma in an individual is disclosed. The method involves administering to the individual a therapeutically effective amount of a therapeutic agent comprising recombinant acid sphingomyelinase. In one embodiment, the therapeutic agent further includes one or more compositions selected from the group consisting of modified enzymes, fusion proteins and constitutively active mutants. In another embodiment, the therapeutic agent further includes a pharmaceutically acceptable excipient.
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Disclosed herein are compositions and methods for treating an individual having a leukemia. In certain aspects, the methods may include administering an I0DVA1 compound and ponatinib to an individual in need thereof for treatment of a leukemia, which may include, for example, TKI-resistant leukemia, TKI-resistant Ph+ B-ALL, Chronic Myelogenous Leukemia (CML), Ph-Positive Acute Lymphoblastic Leukemia (ALL), Ph-like ALL, Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML), MLL-rearranged B-ALL, and VAV3 positive leukemia.
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide non condensés avec un autre cycle, p. ex. ranitidine, furosémide, bufétolol, muscarine
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
66.
SYSTEMS AND METHODS FOR PREDICTING AIRPORT PASSENGER FLOW
A computing device includes a controller to receive passenger data based on airport scans of boarding passes, determine time until takeoff data for passengers, determine passenger flow histograms based on the time until takeoff data, transform the passenger flow histograms into continuous passenger flow profile curves, determine input similarity matrices between a first flight and past flights having scheduled departures on the same day of the week based on input similarity scores, determine output similarity matrices between the first flight and the past flights based on passenger flow profile curves associated with the first flight and the past flights, determine past flights that are most similar to the first flight based on the input similarity matrices and the output similarity matrices, and determine a predicted passenger flow profile curve for the first flight based on the passenger flow profile curves associated with the most similar past flights.
G06Q 10/04 - Prévision ou optimisation spécialement adaptées à des fins administratives ou de gestion, p. ex. programmation linéaire ou "problème d’optimisation des stocks"
G06Q 10/02 - Réservations, p. ex. pour billetterie, services ou manifestations
G06Q 50/40 - Procédés d’affaires s’appliquant à l’industrie du transport
A biphasic membrane-free battery and a triphasic membrane-free battery are provided. The biphasic membrane-free battery includes a housing structure housing: a catholyte phase having a cathode, and an anolyte phase having an anode, the catholyte phase contacting the anolyte phase along an interface. The triphasic membrane-free battery includes a housing structure housing: a catholyte phase having a cathode, and an anolyte phase having an anode, and an electrolyte phase between the catholyte phase and the anolyte phase.
A novel method of making a 3D-shaped 3D graphene (3D2G) is disclosed. The method involves a) 3D printing a catalyst slurry via Direct Ink Writing (DIW); b) depositing the printed slurry using chemical vapor deposition (CVD) to produce a nickel-graphene composite; and c) etching the nickel-graphene composite. The resulting composite is a porous, binder-free structure of pure 3D2G. In one embodiment, the catalyst slurry comprises nickel particles mixed with an organic solvent, a polymer, and a plasticizer. In another embodiment, the organic solvent is dichloromethane, the polymer is poly lactic-co-glycolic acid and the plasticizer is dibutyl phthalate.
A device for continually sensing at least one analyte in a sample fluid via measurement of the analyte is provided. The device includes at least one sensor with surface having a plurality of aptamers that bind to the analyte. The aptamers carry at least one tag that changes in at least one electrical parameter as analyte binds to the aptamers. The surface also has a protective layer that protects the surface from fouling in between the aptamers. The protective layer includes a monolayer of molecules that form a boundary with the sample fluid and the monolayer is a mixed conductivity monolayer.
G01N 33/542 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec inhibition stérique ou modification du signal, p. ex. extinction de fluorescence
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
70.
ELECTROCHEMICAL APTAMER SENSORS WITH APTAMERS BOUND ADJACENT TO THE ELECTRODE
An aptamer sensing device is provided. The aptamer sensing device 200 includes at least one electrode 220. The aptamer sensing device further includes at least one binding feature 230. The aptamer sensing device further includes a plurality of aptamers 270 attached to the binding feature and not individually attached to the electrode, the aptamers further having an attached redox couple 272. The aptamer sensing device is configured to accept a sample fluid 242 including at least one analyte, and the binding feature is positioned relative to the electrode such that a binding of the analyte to the aptamers causes a shape change configuration in the binding feature that increases or decreases a charge transfer from the redox couple to the electrode.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
71.
IONIZABLE LIPIDS, LIPID NANOPARTICLES FOR MRNA DELIVERY AND METHODS OF MAKING THE SAME
A composition including ionizable lipids is provided. Also provided is a composition forming lipid nanoparticle, wherein the composition includes the ionizable lipid, a helper lipid, a sterol, and a PEGylated lipid conjugate. Also provided are methods of making the ionizable lipids. The ionizable lipids can include 2AEOAP2, 2AEOAP4, 2AELAP2, 2AELAP4, Lipid 16A, Lipid 16B, Lipid 16C, Lipid 16B, and Lipid 20B.
C07D 211/62 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile liés en position 4
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A device for continually sensing at least one analyte in a sample fluid via measurement of the analyte is provided. The device includes an optically transparent component adapted for in-vivo placement. The device also includes a plurality of aptamers bound to the optically transparent component. The aptamers are capable of binding to the analyte. Also, the aptamers carry at least one tag that changes in at least one optically measurable property when the aptamers bind to the analyte. Additionally, an optical source and detector coupled to the optically transparent component can measure the optically measurable property of the aptamers.
A device for continually sensing at least one analyte in a sample fluid via measurement of the analyte is provided. The device has a sensor with a surface having a plurality of aptamers that bind to the analyte. The plurality of aptamers carries at least one tag. The surface also has a protective layer that protects the surface from fouling in between the aptamers. The protective layer has a monolayer of molecules that form a boundary with the sample fluid. Further, the monolayer of molecules is a mixed charge monolayer.
G01N 33/542 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec inhibition stérique ou modification du signal, p. ex. extinction de fluorescence
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
Certain aspects described herein include systems and methods for predicting vaccine uptake. A method includes presenting, to a user via a user interface, a set of stimuli; and receiving, from the user via the user interface, a set of ratings associated with the set of stimuli, wherein each respective rating in the set of ratings corresponds with a respective stimuli in the set of stimuli. The method further includes determining a set of judgment variables based on the set of ratings; and generating, with a machine learning model, a vaccine uptake prediction based on the set of judgment variables, wherein the machine learning model is trained to determine a vaccination status of users.
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe
75.
BIOSENSOR FOR PLACEMENT AT SKIN DEPTHS THAT ARE NOT PREDETERMINED
A wearable device for continuous monitoring of at least one analyte is provided. The device includes a plurality of aptamer sensors for a specific analyte and a means to determine at least one location measurement. The sensors are capable of being placed in a distinct location with respect to depth into a user's skin. The location measurement has a distinct measurement response between at least two skin tissues such as epidermis, dermis, and hypodermis. Also, at least one of the sensors is capable of being placed at a distinct tissue location.
A61B 5/1473 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques invasifs, p. ex. introduits dans le corps par un cathéter
Provided herein are methods of potentiating an effect of an anti-cancer drug in a subject diagnosed with cancer, the method including administering to the subject a combination therapy including: an effective amount of 7-ethynyl-5-(2-fluorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (BZD-1); and an anti-cancer drug.
A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A rotating detonation combustor includes a nozzle coupled to the combustor body at or near the exhaust opening to choke the exhaust opening. A rotating detonation combustor may include a diverting plate positioned radially inward of the inlet annulus and inlet channels for diverting flow of a mixture in an axial direction. A rotating detonation combustor may include a combustor body including an outer shell at least partially defining a detonation combustion chamber and extending axially from a base toward an exhaust opening of the detonation combustion chamber. The base defines a passageway in fluid communication with the detonation combustion chamber and includes an inlet annulus for axially directing a second fluid into the passageway and a plurality of inlet channels for radially directing a third fluid into at least one of the passageway or the detonation combustion chamber, and the detonation combustion chamber is free of any inner body.
A probe for positron emission tomography (PET) is disclosed. The probe is selected from the group consisting of yersini-abactin (Ybt) labeled with Copper-64; staphylopine (StP) labeled with Copper-64; yersiniabactin (Ybt) labeled with Zirconium-89; and staphylopine (StP) labeled with Zirconium-89.
22+22+2242+2252+2+ product when the one or more single-site dopants has an oxophilicity that is less than the oxophilicity of Cu or greater than the oxophilicity of Ru.
C25B 11/091 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé d’au moins un élément catalytique et d’au moins un composé catalytiqueÉlectrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé de plusieurs éléments catalytiques ou composés catalytiques
A method of determining an initial concentration of an analyte in a sample fluid is provided. The method includes providing a plurality of irreversible probes (182b), the plurality of irreversible probes (182b) each including at least one binding site configured to bind to an analyte (180). The method further includes introducing a sample fluid (140b) to the irreversible probes (182b) allowing binding of the analyte (180) to the irreversible probes (182b) at the binding site, the analyte 180 binding to the at least one of the plurality of irreversible probes (182b) produces a change in a signal having a signal strength. After the signal strength is unchanged for a period of time, the method includes calculating the initial concentration of the analyte in the sample fluid based on the signal strength.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
81.
2 PRODUCTION FROM ELECTROCATALYTIC WATER REDUCTION COUPLED WITH FORMALDEHYDE OXIDATION VIA A COPPER-SILVER ELECTROCATALYST
377, and a basic anolyte with an aldehyde therein. The aldehyde reacts with the hydroxyl groups from the catholyte to produce hydrogen and the catholyte reacts water therein with the electrons from the anolyte to also produce hydrogen in a highly Faradaic efficient system. Application of the present disclosure not only provides for production of clean hydrogen, but also offers an approach for aldehyde decontamination.
A method of electrocatalytic dual hydrogenation includes loading a first hydrogenation solution and a second hydrogenation solution into a first hydrogenation compartment and a second hydrogenation compartment of an electrocatalytic hydrogenation assembly, in which the first hydrogenation compartment and the second hydrogenation compartment are separated from an electrochemical cell by a hydrogen-permeable anode and a hydrogen-permeable cathode. The method includes applying and maintaining a voltage to the electrochemical cell to reduce a cathode solution and to oxidize an anode solution to provide hydrogen in the cathodic compartment and/or the anodic compartment. The hydrogen may be absorbed through the hydrogen-permeable anode and/or the hydrogen-permeable cathode and hydrogenate an unsaturated substrate in the first hydrogenation solution and/or the second hydrogenation solution. The method includes producing a first hydrogenated product and a second hydrogenated product with a total Faradic efficiency from 150% to 200%.
C25B 9/23 - Cellules comprenant des électrodes fixes de dimensions stablesAssemblages de leurs éléments de structure avec des diaphragmes comprenant des membranes échangeuses d'ions dans ou sur lesquelles est incrusté du matériau pour électrode
C25B 9/00 - Cellules ou assemblages de cellulesÉléments de structure des cellulesAssemblages d'éléments de structure, p. ex. assemblages d'électrode-diaphragmeCaractéristiques des cellules relatives aux procédés
83.
ROTATING DETONATION ENGINES AND RELATED DEVICES AND METHODS
In one embodiment, a combustor (50) includes a nozzle (52) coupled to the combustor body (12) at or near the exhaust opening (26) to choke the exhaust opening (26). In another embodiment, a combustor includes a diverting plate (74) positioned radially inward of the inlet annulus (40) and inlet channels (42) for diverting flow of a mixture in an axial direction. In another embodiment, a combustor (100) includes a combustor body (102) including an outer shell (104) at least partially defining a combustion chamber (108) and extending axially from a hollow base (106) toward an exhaust opening (112) of the combustion chamber (108). The hollow base (106) defines a passageway (126) in fluid communication with the combustion chamber (108) and includes an inlet annulus (142) for axially directing a first fluid (01) into the passageway (126) and a plurality of inlet channels (140) for radially directing a second fluid (F) into at least one of the passageway (126) or the combustion chamber (108), and the combustion chamber (108) is free of any inner body (20).
F23R 7/00 - Chambres de combustion à combustion intermittente ou explosive
F02C 3/14 - Ensembles fonctionnels de turbines à gaz caractérisés par l'utilisation de produits de combustion comme fluide de travail caractérisés par l'aménagement de la chambre de combustion dans l'ensemble
F02C 5/00 - Ensembles fonctionnels de turbines à gaz caractérisés par un fluide énergétique produit par une combustion intermittente
84.
IMPROVED ADDITIVE SOLUTION FOR WHOLE BLOOD PRESERVATION AND STORAGE
A whole blood anticoagulant composition and system including the composition, wherein the composition includes sodium bicarbonate, mannitol, sodium acetate, and magnesium citrate—and may optionally include sodium bisphosphate and/or adenine. The whole blood storage system may include apparatus that allows for whole blood leukoreduction with pH optimization for improved RBC storage. Such a system can provide leukoreduced whole blood for field medical use, and preserve RBCs and maintain or mostly maintain coagulation activity of the whole blood.
Naloxone variants that are both long lasting and responsive are disclosed. One version of the compound has a boron ester functional group and the antagonist compound is capable of a sustained release of antagonist based on reaction with hydrogen peroxide. In addition, a method of treating opioid overdose is disclosed. The method involves administering a therapeutically effective amount of the formulation described above to a patient in need thereof. Administration occurs either intranasally, sublingually or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly.
A method of forming a yellow grease is provided. The method includes delivering a FOG lipid extraction agent into a processing tank. The method further includes preheating an FOG to a temperature of between 35° C. and 95° C. The method further includes mixing the preheated waste grease with the FOG lipid extraction agent in the processing tank to form the yellow grease.
An apparatus may include a processor configured to synthesize a first configuration file associated with a target field-programmable gate array (FPGA), and a second configuration file associated with the target FPGA, wherein first look-up-table (LUT) bits of the first configuration file are the logical inverse of second LUT bits of the second configuration file, and first non-LUT bits of the first configuration file are the same as second non-LUT bits of the second configuration file, and generate a LUT mask indicating which bits of the first configuration file and the second configuration file correspond to the first LUT bits and the second LUT bits by performing a bit-wise exclusive OR operation between the first configuration file and the second configuration file.
G06F 30/331 - Vérification de la conception, p. ex. simulation fonctionnelle ou vérification du modèle par simulation avec accélération matérielle, p. ex. en utilisant les réseaux de portes programmables [FPGA] ou une émulation
A device for measuring one or more analytes in a sample of interstitial fluid or blood is provided. The device comprises at least one EAB sensor using one or more attached redox couples that measure at least one of the analytes. It also includes at least one means to establish fluid communication between the sensor and the sample. The analytes are selected from the group consisting of progesterone, luteinizing hormone (LH), estrogen, follicle stimulating hormone (FSH), their metabolites, and combinations thereof.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/1473 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques invasifs, p. ex. introduits dans le corps par un cathéter
A device for measuring one or more analytes in a sample fluid is provided. The device includes at least one aptamer sensor comprising a plurality of aptamers. The sensor provides a measurement of at least one of the analytes. In addition, the measurement is affected by changes in temperature (“a temperature-dependent response”). The device also includes a means to establish fluid communication between the at least one aptamer sensor and the sample fluid. Further, the device includes at least one temperature sensor and a means for correcting a measurement error due to the temperature-dependent response.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/1459 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale invasifs, p. ex. introduits dans le corps par un cathéter
A61B 5/1473 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques invasifs, p. ex. introduits dans le corps par un cathéter
G01N 27/27 - Association de plusieurs systèmes ou cellules de mesure, chacun mesurant un paramètre différent, dans laquelle les résultats des mesures peuvent être, soit utilisès indépendamment, les systèmes ou les cellules étant physiquement associés, soit combinés pour produire une valeur représentative d'un autre paramètre
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
Provided herein is a vaccine adjuvant containing an N-terminal domain of osteopontin or a fragment thereof. Also provided are conjugates and fusion proteins containing the N-terminal domain of osteopontin conjugated to a pathogen or a protein derived therefrom. A method for potentiating an immune response to an immunizing antigen is also provided, the method including administering to a subject an effective amount of a vaccine adjuvant containing an N-terminal domain of osteopontin. Also provided is a method of vaccinating a subject against SARS-CoV-2, the method including administering to a subject a fusion protein containing the N-terminal domain of osteopontin and the receptor binding domain of SARS-CoV-2 spike glycoprotein. Cellular vaccines and methods of vaccinating a subject with a cellular vaccine are also provided herein.
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A novel composition is provided. The composition is a tetrameric reaction product of heterocyclic 3-thiophenecarboxaldehyde and an aromatic compound, the reaction product being a calix[4]arene. In one embodiment, the present invention is a thiophene functionalized calixarene selected from the group consisting of C-thiopheneresorcin[4]arene and C-thiophenepyrogallol[4]arene. In another embodiment, the thiophene functionalized calixarene further comprises silver nanoparticles.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
C09D 4/00 - Compositions de revêtement, p. ex. peintures, vernis ou vernis-laques, à base de composés non macromoléculaires organiques ayant au moins une liaison non saturée carbone-carbone polymérisable
Systems and methods disclosed herein provide training an artificial neural network (ANN) on buffered input and output samples of an original component within a system such that the ANN is configured to produce a degenerate component, the degenerate component configured to generate the same outputs as the original component; comparing the outputs from the original component to outputs of the degenerate component during actual component operation; and in the event of a failure of the original component, replacing the original component with the degenerate component.
An apparatus may comprise a synapse comprising a first reconfigurable field-effect transistor; a second reconfigurable field-effect transistor connected in parallel to the first reconfigurable field-effect transistor; an input voltage applied to each of the first reconfigurable field-effect transistor and the second reconfigurable field-effect transistor corresponding to an input attribute associated with an error computation; and a current sensor measures a saturation drain current of the first reconfigurable field-effect transistor and the second reconfigurable field-effect transistor and determines a Euclidean error based on the saturation drain current of the FETs
G11C 11/22 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliersÉléments d'emmagasinage correspondants utilisant des éléments électriques utilisant des éléments ferro-électriques
G06N 3/063 - Réalisation physique, c.-à-d. mise en œuvre matérielle de réseaux neuronaux, de neurones ou de parties de neurone utilisant des moyens électroniques
A method for anomaly detection in an operational asset includes collecting a source domain dataset corresponding to a first operating condition of the operational asset, wherein samples from the source domain dataset belong to a healthy class, and a faulty class; collecting a target domain dataset corresponding to a second operation condition of the operational asset, wherein samples from the target domain dataset belong to the healthy class; inputting the source domain dataset and the target domain dataset as input data into a neural network; extracting, by the neural network, features from the input data, wherein a first subset of features is discriminative of the healthy class and a second subset of features is domain invariant; reducing a dimensionality of the features into reduced features; and classifying the reduced features into a normal class and an anomaly class using a one-class classifier.
An implant system for the fusion of the occipitocervical (O-C1) joint is provided. The system has a plate including a horizontal panel, a right vertical panel and a left vertical panel. The horizontal panel has at least two openings. The right vertical panel has at least two openings. The left vertical panel has at least two openings. The system also includes at least four bone fixation fasteners to fix the panels to the occipital condyle and C1 lateral mass using the openings in the panels.
A61B 17/70 - Dispositifs de mise en position ou de stabilisation de la colonne vertébrale, p. ex. stabilisateurs comprenant un liquide de remplissage dans un implant
A positive expiratory pressure-generating device for reducing breathlessness in a subject with one or more pulmonary disorders is disclosed. The device is rigid and hollow and can be held in the mouth of the subject. The device has at least one air chamber, at least one opening in the portion of the device that is held in the mouth and at least one additional airflow orifice. The device is configured to increase expiratory resistance and can be supported by the mouth of the subject without the need for additional support by hands, another device or other means.
A63B 23/18 - Appareils d'exercice spécialement adaptés à des parties déterminées du corps pour améliorer la fonction respiratoire
A63B 21/00 - Appareils de gymnastique pour développer ou fortifier les muscles ou les articulations du corps en surmontant des résistances, avec ou sans dispositifs de mesure
A63B 23/03 - Appareils d'exercice spécialement adaptés à des parties déterminées du corps pour la tête ou le cou pour les muscles du visage
97.
MG ALLOY MESH REINFORCED POLYMER/ECM HYBRID SCAFFOLDS FOR CRITICAL-SIZED BONE DEFECT REGENERATION
The invention relates to biomimetic, biodegradable composites including a magnesium (Mg) alloy mesh and a polymer/extracellular matrix (ECM). These hybrid composites, more particularly, are useful for the fabrication of medical implant devices, e.g., scaffolds, and are effective for bone regeneration. The fabrication process includes creating the Mg alloy mesh, and concurrently electrospinning the polymer and electrospraying the ECM onto the mesh.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A61L 27/44 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire
Provided herein are an ionizable lipid compound, a lipid nanoparticle comprising the ionizable lipid compound, a composition comprising an mRNA formulated in the lipid nanoparticle, and a method of delivering an mRNA to a subject or a cell by administering the composition including an mRNA formulated in the lipid nanoparticle to the subject or cell.
C07C 229/22 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé le squelette carboné étant substitué de plus par des atomes d'oxygène
C07C 229/24 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant plus d'un groupe carboxyle lié au squelette carboné, p. ex. acide aspartique
C07C 229/26 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant plus d'un groupe amino lié au squelette carboné, p. ex. lysine
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Avobenzone complexes are provided, including a complex of avobenzone-RsC5 and a complex of cucurbit[7]uril. Among other uses, the complexes can be used in sunscreen compositions. In one embodiment, the avobenzone complex is from about 0.5 to about 10 weight percent of the sunscreen composition.
An orthopedic implant is provided. The implant includes at least one coating on the surface of the implant. The coating has at least one drug and release of the drug is selectively triggered by inflammation. The coating may comprise one or more ROS-responsive polymers selected from the group consisting of poly(thioketal ß-amino amide) (PTK-BAA), poly(thioacetal ß-amino amide) (PTA-BAA), and poly(ß-amino ester) (PBAE) chemistries.
